Phase

Compound

Indication

Study

Status

Phase III

Cadazolid

Clostridium difficile-associated diarrhea

IMPACT

Ongoing

Macitentan

Pediatric PAH

TOMORROW

Initiating

Macitentan

Portopulmonary hypertension (PoPH)

PORTICO

Ongoing

 

Macitentan

Fontan-palliated

RUBATO

Initiating

Ponesimod

Multiple sclerosis

OPTIMUM

Ongoing

Ponesimod

Multiple sclerosis

POINT

Ongoing

Phase II

 

 

 

 

Cenerimod

Systemic lupus erythematosus

- Ongoing  

Clazosentan

Reversal of vasospasm associated with aneurysmal subarachnoid hemorrhage  REVERSE Ongoing

Dual Orexin Receptor Antagonist 

Insomnia 

-

Ongoing

Endothelin Receptor Antagonist (ACT-132577)

Resistant hypertension

-

Ongoing

Macitentan

Chronic thromboembolic pulmonary hypertension

MERIT

Complete

Phase Ib

Lucerastat

Fabry disease 

-

Complete

Phase I

 

 

 

 

 

 

 

 

 

 

 

 

 

P2Y12 receptor antagonist (ACT-246475)

Acute coronary syndrome

-

Ongoing

CRTH2 receptor antagonist (ACT-774312)

Asthma -

Ongoing

Selective Orexin 1 Receptor Antagonist (ACT-539313)

Anxiety -

Ongoing

T-type Calcium Channel Blocker (ACT-709478)

Epilepsy -

Ongoing

 

Physician, Global Drug Safety 

 

"I am motivated because we can make a difference in our patients' lives."